Intranasal mRNA-LNP vaccination protects hamsters from SARS-CoV-2 infection
Vaca, G. B.; Meyer, M.; Cadete, A.; Hsiao, C. J.; Golding, A.; Jeon, A.; Jacquinet, E.; Azcue, E.; Guan, C. M.; Sanchez-Felix, X.; Pietzsch, C. A.; Mire, C. E.; Hyde, M. A.; Comeaux, M. E.; Williams, J. M.; Sung, J. C.; Carfi, A.; Edwards, D. K.; Bukreyev, A.; Bahl, K.
Show abstract
Intranasal vaccination represents a promising approach for preventing disease caused by respiratory pathogens by eliciting a mucosal immune response in the respiratory tract that may act as an early barrier to infection and transmission. This study investigated immunogenicity and protective efficacy of intranasally administered messenger RNA (mRNA)-lipid nanoparticle (LNP) encapsulated vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Syrian golden hamsters. Intranasal mRNA-LNP vaccination systemically induced spike-specific binding (IgG and IgA) and neutralizing antibodies with similar robustness to intramuscular controls. Additionally, intranasal vaccination decreased viral loads in the respiratory tract, reduced lung pathology, and prevented weight loss after SARS-CoV-2 challenge. This is the first study to demonstrate successful immunogenicity and protection against respiratory viral infection by an intranasally administered mRNA-LNP vaccine.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Synthetic Multiantigen MVA Vaccine COH04S1 Protects Against SARS-CoV-2 in Syrian Hamsters and Non-Human Primates 97%
- Protective efficacy of a SARS-CoV-2 DNA Vaccine in wild-type and immunosuppressed Syrian hamsters 97%
- A self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stability 96%
Similar papers in this journal
- A Whole Virion Vaccine for COVID-19 Produced Via a Novel Inactivation Method: Results from Animal Challenge Model Studies 96%
- A SARS-CoV-2 Spike Ferritin Nanoparticle Vaccine is Protective and Promotes a Strong Immunological Response in the Cynomolgus Macaque Coronavirus Disease 2019 (COVID-19) Model 96%
- Assessment of Immunogenicity and Efficacy of CV0501 mRNA-based Omicron COVID-19 Vaccination in Small Animal Models 96%
Similar papers in this journal
- Rational design of respiratory syncytial virus dimeric F-subunit vaccines in protein and mRNA forms 95%
- The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 Beta (B.1.351) and other variants of concern in preclinical studies. 94%
- Dynamics of humoral and cellular immune responses after homologous and heterologous SARS-CoV-2 vaccination with ChAdOx1 nCoV-19 and BNT162b2 94%
Similar papers in this journal
- A pan-variant mRNA-LNP T cell vaccine protects HLA transgenic mice from mortality after infection with SARS-CoV-2 Beta 95%
- Shared Clinical and Immunologic Features of mRNA Vaccines: Preliminary Results from a Comparative Clinical Study 95%
- Novel Spike-stabilized trimers with improved production protect K18-hACE2 mice and golden Syrian hamsters from the highly pathogenic SARS-CoV-2 Beta variant. 94%
Similar papers in this journal
- A Single Dose of Self-Transcribing and Replicating RNA Based SARS-CoV-2 Vaccine Produces Protective Adaptive Immunity In Mice 96%
- Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19 94%
- mRNA-LNP vaccines against Hepatitis B virus induce protective immune responses in preventive and chronic mouse challenge models 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.